I MabCampath- grenen fik 36/ 77 (46, 8%) af patienterne med asymptomatisk PCR positiv CMV antiviral behandling, og 47/ 77 (61%) af disse patienter fik seponeret MabCampath- behandlingen.
In the MabCampath arm 36/ 77 (46.8%) of patients with asymptomatic PCR positive CMV received antiviral therapy and 47/ 77 (61%) of these patients had MabCampath therapy interrupted.